Navigation Links
Optimizing Patient Participation in Clinical Trials: Attract. Engage. Retain. – eCongress eBox Archives Now Available

Toronto, Canada (PRWEB) July 14, 2014

Throughout this past June 100s of mid-to-senior level executives from across the clinical trials space, representing 38 countries globally, registered for Xtalks 1st Annual eCongress webinar series entitled “Optimizing Patient Participation in Clinical Trials. Attract. Engage. Retain.”

This well-attended eCongress kicked off with internationally renowned R&D expert, Ken Getz, of Tufts CSDD, who provided a Keynote address on Reinventing Drug Development through Patient Centricity.

Throughout this complimentary six-part series the focus remained on the patient/study volunteer, concluding with an innovative panel discussion with advocate and ePatient, Sarah E. Kucharski, querying a panel of industry thought leaders on Challenges & Opportunities Going Forward.

Sample of Important Questions answered in this series:
1.    What are some ways that patient centric clinical trials lower drug development costs and reduce cycle times?

2.    Who or what does today's pharma model revolve around? Is it the physician, the patient, or the market?

3.    How does creating an engaged patient community translate into an increase in patient recruitment?

4.    How would you apply the patient centricity model to engage sites to participate in a trial with a difficult design?

5.    What's the ONE thing pharma should do to see the impact of the ePatient?

6.    Are there differences between ePatients from different parts of the globe?

7.    How do you see the future of trial recruitment changing to take into consideration big data?

8.    Only 3-5% of adults with cancer participate in research. How do we change that?

9.    Should sites be ranked (e.g. top 100 sites for running trials)? And who should rank them? Patients? Sponsors?

10.    Does low clinical trial enrollment have a tech solution? Should the solution target patients or providers?

Sample of Memorable Quotes from this series:

“It’s not about bringing patients to trials; it’s about bringing trials to patients.” Ken Getz @TuftsCSDD

“Accessible and understandable lay results to participants is part of transparency - not enough just to publish on clinical trials registry.” Lilly Clinical OI @Lilly_COI

"All revolutions start with open discussion... Next step is to take it from discussion to action."
Joseph Kim @JoPeKim

“It's an intersection of science, practicality and usability. Without patient input, we cannot progress.” Paulo Moreira, EMD Serono

“We were a very integral part of study to donate our time and data, so "thank you" is nice touch, but being in the loop is better.” “Researchers need to realize there is trial site separation anxiety for patients when studies end. Often they ARE the patients’ healthcare.” Jeri Burtchell @FingoHead

“ePatients can influence change. Their numbers are growing.”
“If we design trials with patients and for patients, there will be less burden on patient lives and will increase trials recruitment.” Annette McKinnon? @anetto

Missed any of the eCongress series? Purchase an eCongress eBox set of the archives for a nominal fee at

Thank you to our esteemed presenters who work tirelessly each day to improve clinical trials and bring safe, new medicines to market and improve the health and lives of patients:

  •     Peter Coë, Executive Director and Co-founder, Tudor Reilly Health
  •     Kenneth A. Getz, MBA, Internationally recognized R&D expert, TUFTS CSDD and Founder, CISCRP
  •     Zachary Hallinan, Director of Patient Communication and Engagement Programs, CISCRP
  •     Ronald Heslegrave, Ph.D., Corporate Chief of Research, William Osler Health System
  •     Joseph Kim, MBA, Director Clinical Operations, Patient Engagement and Recruitment, Shire Pharmaceuticals (now Senior Advisor, Clinical Development Innovation, Eli Lilly and Company)
  •     Sarah E. Kucharski, Patient Advocate and ePatient, CEO/Chairman and Founder, FMD Chat
  •     Jerry Matczak, Community Manager, Lilly Clinical Open Innovation, Eli Lilly and Company
  •     Paulo Moreira, VP – GCO, Head of External Innovation, EMD Serono
  •     Christine Pierre, President, Society for Clinical Research Sites

Thank you to our Media and Supporting Partners:

Canadian Clinical Trials Coordinating Centre (CCTCC)
Clinical Research Association of Canada (CRAC)
SCRS (Society for Clinical Research Sites)
Rebar Interactive

And special thanks to:
CISCRP (The Center for Information and Study on Clinical Research Participation)

eCongress is a division of Xtalks, powered by Honeycomb Worldwide Inc. Led by global industry thought leaders, each eCongress is a month-long webinar series, at your fingertips, which delivers practical, real-world insights and solutions to some of your industry’s biggest challenges.

Offered in a convenient, interactive and timely format, each eCongress is free to attend and highlights best practices, case studies and regulatory updates with the goal of facilitating proactive discussion and offering timely solutions around key industry issues.

We hope you have enjoyed this eCongress and have learned some new, innovative ways to optimize patient participation in clinical trials for all stakeholders involved – most notably the research volunteer.

If you would like to contribute ideas for future eCongress series, contact us directly or tweet us at #eCongress. And stay tuned for upcoming details on our next eCongress series at including:

  • Big Data for Big and Small Pharma: A Prescription for Success? and,
  • Orphan Drugs & Rare Diseases: Advancing Drug Development and Patient Access

Michelle Tran
Tel: +1 (416) 977-6555 ext 284
Email: mtran(at)xtalks(dot)com

Read the full story at

Source: PRWeb
Copyright©2014 Vocus, Inc.
All rights reserved

Related biology technology :

1. Country and Site Selection: Optimizing Protocol Planning Decisions by Leveraging Data Through Custom Algorithms, New Webinar Hosted by Xtalks
2. Optimizing Clinical Trials Outcomes through Computer Assisted Design, New Life Science Webinar Hosted by Xtalks
3. Optimizing Assays from FFPE for Biomarker Strategies, New Life Science Webinar Hosted by Xtalks
4. Terascala Advances Its Vision of Optimizing High-Performance Computing Workflows for Faster Time to Results
5. ARUP Laboratories Pathologist, Ronald L. Weiss, MD, Honored With Lifetime Achievement Award for Contributions to Patient Care and Pathology
6. Theravalues Confirms Beneficial Effects of Theracurmin™ on Diastolic Function in Hypertensive Patients
7. Bayer HealthCares Cotavance® Drug Eluting Balloon With Paccocath® Technology Reduced Five-Year Target Lesion Revascularization Rates by 59 Percent in PAD Patients Compared to Those Treated With Uncoated Balloon
8. New Subanalyses of RE-LY® Trial Evaluate PRADAXA in Subsets of Patients with Non-Valvular Atrial Fibrillation
9. Nations Best Health Care Organizations for Patient Satisfaction, Core Measures Honored by Press Ganey
10. Antelope Valley Hospital Converts to Masimo rainbow SET for State-of-the-Art Noninvasive Patient Monitoring Capabilities
11. Clionsky Neuro Systems (CNS-Neuro) Announces Publication of Study Finding Elderly Patients Unable to Recognize Their Memory Loss
Post Your Comments:
(Date:5/19/2016)... ... May 19, 2016 , ... KCAS Bioanalytical and Biomarker Services, ... Director, Large Molecule & Biomarker Bioanalysis. , Dr. Siddiqui has more than 15 ... for preclinical and clinical safety programs. “We’ve seen significant demand for, and we ...
(Date:5/18/2016)... 2016 The Biotech industry continues to ... that there are no opportunities ahead. Today, has on ... THLD ), Seattle Genetics Inc. (NASDAQ: SGEN ... Corp. (NASDAQ: OPHT ). Sign up now to ... Threshold Pharmaceuticals Inc.,s shares gained ...
(Date:5/17/2016)... -- Haselmeier announces the launch by Merck ... EMA, the European Medicines Agency. Originally launched in 2011 ... new pen version includes enhancements to further improve the ... patients during use. Its enhanced design has ... with a larger display window that improves the readability ...
(Date:5/17/2016)... BASEL, Switzerland , May 17, 2016 /PRNewswire/ ... sciences company located in Basel, Switzerland ... an investigational oral inhibitor of P38 mitogen-activated protein ... ) , Strekin will build the ... Pamapimod in indications in which MAP Kinases play ...
Breaking Biology Technology:
(Date:5/9/2016)... UAE, May 9, 2016 Elevay ... comes to expanding freedom for high net worth professionals ... in today,s globally connected world, there is still no ... could ever duplicate sealing your deal with a firm ... passports by taking advantage of citizenship via investment programs ...
(Date:4/28/2016)... 28, 2016 First quarter 2016:   ... compared with the first quarter of 2015 The gross ... M (loss: 18.8) and the operating margin was 40% (-13) ... Cash flow from operations was SEK 249.9 M (21.2) , ... is unchanged, SEK 7,000-8,500 M. The operating margin for ...
(Date:4/19/2016)... The new GEZE SecuLogic access ... "all-in-one" system solution for all door components. It can ... door interface with integration authorization management system, and thus ... minimal dimensions of the access control and the optimum ... offer considerable freedom of design with regard to the ...
Breaking Biology News(10 mins):